Asthma & COPD Market Report 2016-2026

喘息&COPDの世界市場2016-2026

◆タイトル:Asthma & COPD Market Report 2016-2026
◆商品コード:VGAIN61125
◆調査・発行会社:visiongain
◆発行日:2016年10月
◆ページ数:314
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Sigle User(1名利用)GBP1,999 ⇒換算¥309,845見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥464,845見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥774,845見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

当調査レポートでは、喘息&COPDの世界市場について調査・分析し、喘息&COPDの世界市場規模、市場動向、市場予測、関連企業情報などを含め、以下の構成でお届けいたします。
1. レポート概要

2. 喘息&COPD治療の概要

3. 喘息&COPD治療:世界市場2016-2026

4. 気管支拡張薬単剤治療市場2016-2026

5. 抗炎症薬市場2016-2026

6. 配合剤市場2016-2026

7. 主要国市場2016-2026

8. 喘息&COPD治療市場における主要企業

9. 喘息&COPD治療のパイプライン分析2016-2026

10. 喘息&COPD治療市場の定性分析2016-2026

11. 結論

12. 用語集

Visiongain’s comprehensive new 313 page report reveals that the global asthma & COPD market will achieve revenues of $33.2bn in 2016.

Are you involved in the asthma & COPD market or intend to be? If so, then you must read this report.
It’s vital that you keep your knowledge up to date. You need this report.

Market scope: Asthma & COPD are among the most common and debilitating respiratory conditions. Drugs for the treatment of these conditions fall into 3 main categories: Bronchodilator monotherapy, anti-inflammatory drugs and combination drugs. Visiongain assesses how these three submarkets and the 12 largest national markets will evolve over the forecast period.The competitive landscape is further illustrated with examination of the 7 market leading manufacturers.

The asthma & COPD Market 2016-2026 report responds to your need for definitive market data:

• Where are the asthma & COPD market opportunities?
- 248 tables, charts, and graphs reveal market data allowing you to target your strategy more effectively

• When will the asthma & COPD market grow?
- Global, regional and asthma & COPD submarket forecasts and analysis from 2016-2026 illustrate the market progression

• Which asthma & COPD submarkets will flourish from 2016-2026?
- Individual application forecasts and analysis demonstrate the prospects
• Combination drugs forecast 2016-2026
• Anti-inflammatory drugs forecast 2016-2026
- Corticosteroids forecast 2016-2026
- Anti-Leukotrienes forecast 2016-2026
- Monoclonal antibodies forecast 2016-2026
- Other anti-inflammatories forecast 2016-2026
• Bronchodilator monotherapy forecast 2016-2026
- Short-acting beta2-agonist (SABAs) forecast 2016-2026
- Long-acting beta2-agonist (LABAs) forecast 2016-2026
- Anticholinergics forecast 2016-2026

• Where are the regional asthma & COPD market opportunities from 2016-2026?
- Focused regional forecasts and analysis explore the future opportunities
- US forecast 2016-2026,
- China forecast 2016-2026
- Japan forecast 2016-2026
- India forecast 2016-2026
- Germany forecast 2016-2026
- UK forecast 2016-2026
- France forecast 2016-2026
- Mexico forecast 2016-2026
- Brazil forecast 2016-2026
- Russia forecast 2016-2026

• What are the factors influencing asthma & COPD market dynamics?
- SWOT / Porter’s Five Forces analysis explores the factors.
- Research and development (R&D) strategy
- Technological issues and constraints.
- Supply and demand dynamics
- Competition from new product types
- Increasing specialisation by leading players
- Advances in product quality

• Who are the leading asthma & COPD companies?
- Examine competitive positioning, product portfolios, R&D activity, M&A activity, and future outlook.
- GSK
- Boehringer Ingelheim
- AstraZeneca
- Merck & Co. Inc (Merck)
- Novartis
- Roche
- Teva

• Who should read this report?
- Anyone within the asthma & COPD value chain, including
- CEO’s
- COO’s
- CIO’s
- Business development managers
- Marketing managers
- Suppliers
- Technologists
- Investors
- Banks
- Government agencies
- Contractors

【レポートの目次】

1. Report Overview
1.1 Global Asthma and COPD Therapies Market Overview
1.2 Global Asthma and COPD Therapies Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Visiongain Reports
1.10 About Visiongain

2. Introduction to Asthma and COPD Therapies
2.1 The Pharmaceutical Industry: A Very Brief Overview
2.2 Classifying Respiratory Diseases: Obstructive and Restrictive
2.2.1 Classifying Respiratory Diseases: Obstructive and Restrictive
2.3 What is Asthma?
2.3.1 Trends in Asthma Prevalence
2.3.2 Pathophysiology of Asthma
2.3.3 Symptoms of Asthma
2.3.4 Causes and Triggers for Asthma
2.3.5 Treatment of Asthma
2.3.6 Guidelines for Asthma Treatment
2.3.7 Drug Treatments for Asthma
2.3.8 Drug Delivery Methods in Asthma
2.4 What is Chronic Obstructive Pulmonary Disease (COPD)?
2.4.1 Trends in COPD Prevalence
2.4.2 Pathophysiology of COPD
2.4.3 Signs and Symptoms of COPD
2.4.4 Treatment of COPD
2.4.5 Drug Treatments for COPD
2.4.6 Guidelines for COPD Treatment
2.5 Major Drug Classes in the Treatment of Asthma and COPD
2.5.1 Bronchodilators
2.5.1.1 Beta2-Agonists
2.5.1.2 Anticholinergics
2.5.2 Anti-Inflammatory Drugs
2.5.2.1 Corticosteroids
2.5.2.2 Leukotriene Receptor Antagonists
2.5.2.3 Monoclonal Antibodies in the Treatment of Respiratory Disease
2.5.3 Combination Drugs
2.6 Phases of Clinical Trials
2.7 Scope of this Report
2.8 Currency Exchange Rates in This Report

3. Asthma and COPD Therapies: Global Market 2016-2026
3.1 The Global Respiratory Drugs Market by Therapeutic Area
3.2 The Global Asthma and COPD Therapies Market in 2016
3.2.1 Leading Asthma and COPD Therapies
3.2.2 Leading Companies in the Asthma and COPD Therapies Market
3.3 Global Asthma and COPD Therapies Market: Sales Forecast by Therapeutic Area, 2016-2026
3.3.1 Global Asthma Therapies Market: Sales Forecast, 2016-2026
3.3.2 Global COPD Therapies Market: Sales Forecast 2016-2026
3.4 Global Asthma and COPD Therapies Market: Sales Forecast by Drug Class 2016-2026
3.5 Combination Drugs Lead the Asthma and COPD Therapies Market
3.6 How Will Segmental Shares Change to 2026
3.6.1 Global Asthma and COPD Therapies Market: Drivers and Restraints 2016-2026
3.7 Asthma and COPD Therapies: Trends and Developments
3.7.1 FDA Requires Replacement of CFC Inhalers with HFA Inhalers
3.7.2 The WISDOM Trial: Will Steroids Lose Their Role in COPD?

4. Bronchodilator Monotherapy Market 2016-2026
4.1 Introduction to Bronchodilator Monotherapy
4.2 The Bronchodilator Monotherapy Market in 2015
4.2.1 Leading Bronchodilators in 2015
4.2.2 Bronchodilator Monotherapy: Market Forecast 2016-2026
4.2.3 How Will Market Shares by Drug Class Change to 2026?
4.3 The Anticholinergics Market 2016-2026
4.3.1 Leading Anticholinergics in 2015
4.3.2 Anticholinergics: Market Forecast 2016-2026
4.3.3 Market Share of Leading Anticholinergics to 2026
4.3.4 Spiriva (tiotropium. Boehringer Ingelheim)
4.3.4.1 Spiriva: Sales Forecast 2016-2026
4.3.4.2 Spiriva: Recent Developments
4.3.5 Atrovent (ipratropium, Boehringer Ingelheim)
4.3.5.1 Atrovent: Sales Forecast 2016-2026
4.3.6 Eklira/Tudorza/Bretaris (alcidinium, AstraZeneca/Menarini)
4.3.6.1 Eklira/Tudorza/Bretaris: Sales Forecast 2016-2026
4.4 The SABAs Market 2016-2016
4.4.1 Leading SABAs in 2015
4.4.2 SABAs: Market Forecast 2016-2026
4.4.3 Market Share of Leading SABAs to 2026
4.4.4 Ventolin (salbutamol, GSK)
4.4.4.1 Ventolin: Sales Forecast 2016-2026
4.4.5 ProAir (salbutamol, Teva)
4.4.5.1 ProAir: Sales Forecast 2016-2026
4.4.6 Proventil (salbutamol, Merck)
4.4.6.1 Proventil: Sales Forecast 2016-2026
4.4.7 Xopenex (levosalbutamol, Dainippon Sumitomo)
4.4.7.1 Xopenex: Sales Forecast 2016-2026
4.5 The Long-Acting Beta2-Agonist (LABA) Market 2016-2026
4.5.1 Leading LABAs in 2015
4.5.2 LABAs: Market Forecast 2016-2026
4.5.3 Market Share of Leading LABAs to 2026
4.5.4 Foradil (formoterol, Merck/Novartis
4.5.4.1 Foradil: Sales Forecast 2016-2026
4.5.5 Brovana (arfomoterol, Dainippon Sumitomo)
4.5.5.1 Brovana: Sales Forecast 2016-2026
4.5.6 Arcapta/Onbrez (indacaterol, Novartis)
4.5.6.1 Arcapta/Onbrez: Sales Forecast 2016-2026
4.5.7 Severent (salmeterol, GSK)
4.5.7.1 Serevent: Sales Forecast 2016-2026

5. Anti-inflammatory Drugs Market 2016-2026
5.1 Introduction to Anti-Inflammatory Drugs
5.2 The Anti-Inflammatory Drugs Market in 2015
5.2.1 Leading Anti-Inflammatory Drugs in 2015
5.2.2 Anti-Inflammatory Drugs: Market Forecast 2016-2026
5.2.3 How Will Market Shares by Drug Class Change to 2026?
5.3 The Corticosteroids Market 2016-2026
5.3.1 Leading Corticosteroids in 2015
5.3.2 Corticosteroids: Market Forecast 2016-2026
5.3.3 Market Share of Leading Corticosteroids to 2026
5.3.4 Flixotide/Flovent (fluticasone propionate, GSK)
5.3.4.1 Flixotide/Flovent: Sales Forecast 2016-2026
5.3.5 Pulmicort (budesonide, AstraZeneca)
5.3.5.1 Pulmicort: Sales Forecast 2016-2026
5.3.6 QVAR (beclometasone, Teva)
5.3.6.1 QVAR: Sales Forecast 2016-2026
5.3.7 Asmanex (mometasone, Merck)
5.3.7.1 Asmanex: Sales Forecast 2016-2026
5.4 The Anti-Leukotrienes Market 2016-2026
5.4.1 Leading Anti-Leukotrienes in 2015
5.4.2 Anti-Leukotrienes: Market Forecast 2016-2026
5.4.3 Market Share of Leading Anti-Leukotrienes to 2026
5.4.4 Singulair (montelukast, Merck)
5.4.4.1 Singulair: Sales Forecast 2016-2026
5.5 The Monoclonal Antibodies Market 2016-2026
5.5.1 Monoclonal Antibodies: Market Forecast 2016-2026
5.5.2 Market Share of Leading Monoclonal Antibodies to 2026
5.5.3 Xolair (omalizumab, Novartis/Roche)
5.5.3.1 Xolair: Sales Forecast 2016-2026
5.5.4 Cinquil (reslizumab, Teva)
5.5.4.1 Cinquil: Sales Forecast 2016-2026
5.5.5 Nucala (Mepolizumab, GSK)
5.5.5.1 Nucala: Sales Forecast 2016-2026
5.5.6 Benralizumab (MEDI-563, AstraZeneca/Kyowa Hakko Kirin)
5.5.6.1 Benralizumab: Sales Forecast 2016-2026
5.5.7 Lebrikizumab (RG3637, Roche)
5.5.7.1 Lebrikizumab: Sales Forecast 2016-2026
5.5.8 Dupilumab (REGN668, Regeneron/Sanofi)
5.5.8.1 Dupilumab: Sales Forecast 2016-2026

6. Combination Drugs Market 2016-2026
6.1 Introduction to Combination Drugs
6.1.1 Leading Combination Drugs in 2015
6.1.2 Combination Drugs: Market Forecast 2016-2026
6.1.3 How Will Market Shares by Drug Change to 2026?
6.1.4 Advair/Seretide (fluticasone/salmeterol, GSK)
6.1.4.1 Advair/Seretide: Sales Forecast 2016-2026
6.1.5 Symbicort (budesonide/formoterol fumarate, AstraZeneca)
6.1.5.1 Symbicort: Sales Forecast 2016-2026
6.1.5.2 Symbicort: The SMART Concept
6.1.6 Combivent (ipratropium/salbutamol, Boehringer Ingelheim)
6.1.6.1 Combivent: Sales Forecast 2016-2026
6.1.7 Dulera (formoterol/mometasone, Merck)
6.1.7.1 Dulera: Sales Forecast 2016-2026
6.1.8 Breo/Relvar Ellipta (vilanterol/fluticasone furoate, GSK)
6.1.8.1 Breo/Relvar: Sales Forecast 2016-2026
6.2 Recently Launched Combination Drugs

7. Leading National Markets 2016-2026
7.1 Regional Breakdown of the Global Asthma and COPD Therapies Market
7.2 Global Asthma and COPD Therapies Market; Regional Forecasts 2016-2026
7.2.1 How Will Regional Market Shares Change to 2026?
7.2.2 National Breakdown of the Global asthma and COPD Therapies Market
7.2.3 Global Asthma and COPD Therapies Market: National Markets Forecast 2016-2026
7.2.4 How Will National Market Shares Change to 2026?
7.3 The US Asthma and COPD Therapies Market 2016-2026
7.3.1 The US Asthma and COPD Therapies Market Forecast 2016-2026
7.3.2 US Asthma and COPD Therapies Market Trends and Developments
7.3.2.1 Increasing COPD Prevalence in the US
7.3.2.2 FDA Issues Draft Guidance on Generic Inhaler Bioequivalence
7.3.2.3 Pharmacy Benefit Managers Alter Formulary Status of Advair
7.4 Japanese Asthma and COPD Therapies Market 2016-2026
7.4.1 Japanese Asthma and COPD Therapies Market Forecast 2016-2026
7.4.2 Japanese Asthma and COPD Therapies Market: Trends and Developments
7.4.2.1 Is Generic Penetration to Reach 60% by 2018?
7.4.2.2 Japanese Pharmaceutical Industry Regulatory Reform
7.5 EU5 Asthma and COPD Therapies Market 2016-2026
7.5.1 German Asthma and COPD Therapies Market Forecast 2016-2026
7.5.2 French Asthma and COPD Therapies Market Forecast 2016-2026
7.5.3 UK Asthma and COPD Therapies Market Forecast 2016-2026
7.5.4 Italian Asthma and COPD Therapies Market Forecast 2016-2026
7.5.5 Spanish Asthma and COPD Therapies Market Forecast 2016-2026
7.5.6 EU5 Asthma and COPD Therapies Market: Trends and Developments
7.5.6.1 Germany: Reform of AMNOG Pharmaceutical Rebate Law
7.5.6.2 France: Social Security Finance Bill 2015
7.5.6.3 UK: Improving Asthma and COPD Patient Outcomes
7.5.6.4 Italy: Austerity Measures Limiting Growth
7.5.6.5 Spain: The Start of Recovery in the Spanish Economy
7.6 BRIC Asthma and COPD Therapies Market 2016-2026
7.6.1 Chinese Asthma and COPD Therapies Market Forecast 2016-2026
7.6.2 Chinese Asthma and COPD Therapies Market: Trends and Developments
7.6.2.1 China’s Industrial Future and Asthma/COPD
7.6.2.2 Expansion of Healthcare Coverage and Reimbursement
7.6.2.3 Price Controls and the Anhui Model
7.6.3 Brazilian Asthma and COPD Therapies Market Forecast 2016-2026
7.6.4 Brazilian Asthma and COPD Therapies Market: Trends and Developments
7.6.4.1 Increasing Access to Medicines
7.6.5 Indian Asthma and COPD Therapies Market Forecast 2016-2026
7.6.6 Indian Asthma and COPD Therapies Market: Trends and Developments
7.6.6.1 Drug Prices Control Order 2013
7.6.6.2 Expansion of Healthcare Provision
7.6.7 Russian Asthma and COPD Therapies Market Forecast 2016-2026
7.6.8 Russian Asthma and COPD Therapies Market: Trends and Developments
7.6.8.1 No Embargo on Foreign Drug Imports
7.6.8.2 Pharma2020 and the Russian Pharmaceutical Industry
7.7 Mexican Asthma and COPD Therapies Market 2016-2026
7.7.1 Mexican Asthma and COPD Therapies Market Forecast 2016-2026
7.7.2 Mexican Asthma and COPD Therapies Market: Trends and Developments
7.7.2.1 Seguro Popular: Mexican Healthcare Reform
7.7.2.2 COFEPRIS: Regulatory Changes and Improvements
7.7.2.3 Mexico’s Agreement for Innovation

8. Leading Companies in the Asthma and COPD Therapies Market
8.1 Asthma and COPD Therapies: Increasing Competition
8.2 Leading Companies in Asthma and COPD in 2015
8.3 Leading Companies: Market Forecast 2016-2026
8.4 How Will Leading Companies’ Market Shares Change to 2026?
8.5 GSK
8.5.1 GSK: Asthma and COPD Therapies
8.5.2 GSK: Sales Forecast 2016-2026
8.5.3 GSK: Products in Development
8.5.4 GSK: Recent Developments
8.5.4.1 Recently Launched Combination Drugs
8.5.4.2 GSK Divests OTC Products
8.5.4.3 GSK Asset Swap with Novartis to Restructure Consumer Health
8.5.4.4 GSK Presents Data on Eosinophil Levels and COPD
8.6 Boehringer Ingelheim
8.6.1 Boehringer Ingelheim: Asthma and COPD Therapies
8.6.2 Boehringer Ingelheim: Sales Forecast 2016-2026
8.6.3 Boehringer Ingelheim: Asthma and COPD Product Development Ceased
8.6.4 Boehringer Ingelheim: Recent Developments
8.6.4.1 Expansion of Respimat Manufacturing Capacity
8.6.4.2 Respimat Safety Concerns and the TIOSPIR Study
8.6.4.3 Ben Venue Laboratories Shut Down
8.6.4.4 Sale of Roxane Laboratories
8.6.4.5 Spiloto Respimat and the PHYSACTO Study
8.7 AstraZeneca
8.7.1 AstraZeneca: Asthma and COPD Therapies
8.7.2 AstraZeneca: Sales Forecast 2016-2026
8.7.3 AstraZeneca: Products in Development
8.7.4 AstraZeneca: Recent Developments
8.7.4.1 AstraZeneca Acquires Almirall’s Respiratory Portfolio
8.7.4.2 Acquisition of Pearl Therapeutics Expanded AstraZeneca’s Combination Drug Pipeline
8.7.4.3 AstraZeneca Rejects Pfizer Takeover Bid
8.7.4.4 AstraZeneca Acquires Right to Actavis’ Branded Respiratory Portfolio in US and Canada
8.7.4.5 Takeda Respiratory Portfolio Acquisition
8.8 Merck & Co. (Merck)
8.8.1 Merck: Asthma and COPD Therapies
8.8.2 Merck: Sales Forecast 2016-2026
8.8.3 Merck: Products in Development
8.8.4 Merck: Recent Developments
8.8.4.1 Bayer Acquires Merck’s Consumer Health Business
8.8.4.2 FDA Rejects Singulair OTC Switch
8.8.4.3 Takeda Ended Co-Promotion of Daxas with Merck
8.9 Novartis
8.9.1 Novartis: Asthma and COPD Therapies
8.9.2 Novartis: Sales Forecast 2016-2026
8.9.3 Novartis: Products in Development
8.9.4 Novartis: Recent Developments
8.9.4.1 Novartis Restructures Following Strategic Review
8.9.4.2 Novartis Presents Data on Ultibro and Seebri
8.9.4.3 Pfizer Promotes Two Novartis COPD drugs in the UK
8.10 Roche
8.10.1 Roche: Asthma and COPD Therapies
8.10.2 Roche: Sales Forecast 2016-2026
8.10.3 Roche: Products in Development
8.11 Teva
8.11.1 Teva: Asthma and COPD Therapies
8.11.2 Teva: Sales Forecast 2016-2026
8.11.3 Teva: Products in Development
8.11.4 Teva: Recent Developments
8.11.4.1 Launch of DuoResp Spiromax

9. Asthma and COPD Therapies Pipeline Analysis 2016-2026
9.1 A Strong Asthma and COPD Pipeline
9.2 The Bronchodilators Pipeline
9.3 Bronchodilators: Phase 3 Pipeline
9.3.1 PX1439 and PX1442 (Prosonix)
9.3.2 PT001 (glycopyrronium, AstraZeneca)
9.3.3 Spiriva Respimat (tiotropium, Boehringer Ingelheim)
9.3.4 GW642444 (vilanterol, GSK)
9.3.5 KRP-AB1102 (aclidinium, Kyorin Pharmaceutical)
9.3.6 Seebri Breezhaler (glycopyrronium, Novartis/Vectura)
9.3.7 QVAR BAI (beclometasone, Teva)
9.3.8 Albuterol MDPI/Albuterol RespiClick (salbutamol, Teva)
9.4 The Anti-Inflammatory Drugs Pipeline
9.5 Anti-Inflammatory Drugs: Phase 3 Pipeline
9.5.1 PSX1001 and PSX1050 (fluticasone propionate pMDI, Prosonix)
9.5.2 Masitinib (tyrosine kinase inhibitor, AB Science)
9.5.3 Inhaled Alpha-1 Antitrypsin (Kamada/Chiesi Farmaceutici)
9.5.4 VR506 (fluticasone propionate DPI, Vectura)
9.5.5 Favolir (budesonide, Vectura)
9.6 The Combination Drugs Pipeline
9.7 Combination Drugs: Phase 3 Pipeline
9.7.1 Seriveo (fluticasone/salmeterol, Circassia) (Formerly PSX2005 (Prosonix))
9.7.2 Duaklir Genuair (LAS40464) (aclidinium/formoterol, AstraZeneca)
9.7.3 Bevespi Aerosphere (PT003) (glycopyrronium/formoterol, AstraZeneca)
9.7.4 Tiotropium/Olodaterol Fixed-Dose Combination (LAMA/LABA, Boehringer Ingelheim)
9.7.5 Easyhaler Combination Drugs (Orion)
9.7.6 VR632 (ICS/LABA, Vectura/Sandoz)
9.8 Other Asthma and COPD Drugs Pipeline

10. Qualitative Analysis of the Asthma and COPD Therapies Market 2016-2026
10.1 SWOT Analysis of the Asthma and COPD Therapies Market
10.2 Strengths
10.2.1 Increasing Prevalence and Disease Burden
10.2.2 High Costs of Treatment
10.2.3 The Changing Perception of COPD
10.2.4 Patient Education: Understanding the Severity of Respiratory Disease
10.2.5 Lifecycle Management Strategies to Counter Patent Expiry
10.2.6 Advanced Inhaler Technologies to Counter Generic Erosion
10.2.7 Developments in Diagnostics
10.2.7.1 Diagnostic Imaging: Parametric Response Mapping for COPD
10.2.7.2 Biological Markers in COPD
10.3 Weaknesses
10.3.1 Under-Diagnosis: the ‘Ghost Population’
10.3.2 Side-Effects of Drug Classes
10.3.3 Patent Cliff for Devices
10.3.4 Low Patient Adherence
10.3.5 Costing Pressures in both Developed and Emerging Markets
10.4 Opportunities
10.4.1 Patient Phenotyping and Personalised Medicine
10.4.2 A Strong R&D Pipeline
10.4.3 Ultra-Long-Acting Beta2-Agonists
10.4.4 Muscarinic Antagonists and Beta2-Agonists (MABAs)
10.4.5 Monoclonal Antibodies
10.4.6 LAMA/LABA Combinations
10.4.7 Opportunities in Telehealth
10.5 Threats
10.5.1 Patent Expiry and Generic Competition
10.5.2 Pharmacy Benefit Managers and Cost Control
10.5.3 The WISDOM Trial Could Reduce Steroid Use in COPD
10.6 Porter’s Five Forces Analysis of the Asthma and COPD Therapies Market
10.6.1 Rivalry among Competitors [Medium]
10.6.2 Threat of New Entrants [Medium]
10.6.3 Power of Suppliers [Medium]
10.6.4 Power of Buyers [High]
10.6.5 Threat of Substitutes [Low]

11. Conclusions
11.1 Asthma and COPD Therapies: A Maturing Market
11.2 The Global Asthma and COPD Therapies Market in 2015
11.3 Current Leading Asthma and COPD Therapies Segments
11.3.1 Leading Asthma and COPD Therapies
11.3.2 Leading Asthma and COPD Therapies Companies
11.4 Leading Regional and National Markets
11.5 Global Asthma and COPD Therapies Market Forecast 2016-2026
11.6 The Future of the Asthma and COPD Therapies Market
11.6.1 Growth in Anti-Inflammatory and Combination Drugs
11.6.2 Personalised Medicine
11.6.3 Unmet Needs in Asthma and COPD
11.7 Strategies for Growth in 2016-2026

12. Glossary

Table of Tables
Table 2.1 Classification of Respiratory Diseases, 2016
Table 2.2 Causes of Asthma, 2016
Table 2.3 Triggers of Asthma, 2016
Table 2.4 Clinical Trial Phases
Table 2.5 Currency Exchange Rates, 2015
Table 3.1 World Respiratory Drugs Market: Revenues ($m) and Market Shares (%) by Therapeutic Area, 2015
Table 3.2 Top 10 Asthma and COPD Therapies: Revenue ($m) and Market Shares (%), 2015
Table 3.3 World Asthma and COPD Therapies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
Table 3.4 World Asthma Therapies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
Table 3.5 World COPD Therapies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
Table 3.6 Global Asthma and COPD Therapies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), by Drug Class, 2015-2026
Table 3.7 Market Shares (%) of Leading Asthma and COPD Therapies Market Segments, by Drug Class, 2015, 2020 and 2026
Table 4.1 Bronchodilator Monotherapy Market: Revenues ($m) and Market Shares (%) by Drug Class, 2015
Table 4.2 Leading Bronchodilators: Revenues ($m) and Market Shares (%), 2015
Table 4.3 Bronchodilator Monotherapy Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug Class, 2015-2026
Table 4.4 Leading Anticholinergics: Revenues ($m) and Market Shares (%), 2015
Table 4.5 Anticholinergics Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2015-2026
Table 4.6 Anticholinergics Market: Market Shares (%) by Drug, 2015, 2020 and 2026
Table 4.7 Boehringer Ingelheim: Spiriva Revenue ($m), AGR (%) and CAGR (%), 2015-2026
Table 4.8 Boehringer Ingelheim: Atrovent Revenue ($m), AGR (%) and CAGR (%), 2016-2026
Table 4.9 AstraZeneca/Menarini: Eklira/Tudorza/Bretaris Revenue ($m), AGR (%) and CAGR (%), 2015-2026
Table 4.10 Leading SABAs in 2015
Table 4.11 SABAs Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2015-2026
Table 4.12 SABAs Market: Market Shares (%) by Drug, 2015, 2020 and 2026
Table 4.13 GSK: Ventolin Revenue ($m), AGR (%) and CAGR (%), 2015-2026
Table 4.14 Teva: ProAir Revenue ($m), AGR (%) and CAGR (%), 2015-2026
Table 4.15 Merck: Proventil Revenue ($m), AGR (%) and CAGR (%), 2015-2026
Table 4.16 Dainippon Sumitomo: Xopenex Revenue ($m), AGR (%) and CAGR (%), 2015-2026
Table 4.17 Leading LABAs: Revenues ($m) and Market Shares (%), 2015
Table 4.18 LABAs Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2015-2026
Table 4.19 Leading LABAs: Market Shares (%) by Drug, 2015, 2020 and 2026
Table 4.20 Merck/Novartis: Foradil Revenue ($m), AGR (%) and CAGR (%), 2015-2026
Table 4.21 Dainippon Sumitomo: Brovana Revenue ($m), AGR (%) and CAGR (%), 2015-2026
Table 4.22 Novartis: Arcapta/Onbrez Revenue ($m), AGR (%) and CAGR (%), 2015-2026
Table 4.23 GSK: Serevent Revenue ($m), AGR (%) and CAGR (%), 2015-2026
Table 5.1 Anti-Inflammatory Drugs Market: Revenues ($m) and Market Shares (%) by Drug Class, 2015
Table 5.2 Leading Anti-Inflammatory Drugs: Revenues ($m) and Market Shares (%), 2015
Table 5.3 Anti-Inflammatory Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug Class, 2015-2026
Table 5.4 Anti-Inflammatory Drugs Market: Revenues ($m) and Market Shares (%) by Drug Class, 2020 and 2026
Table 5.5 Leading Corticosteroids: Revenues ($m) and Market Shares (%), 2015
Table 5.6 Corticosteroids Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2015-2026
Table 5.7 Corticosteroids Market: Market Share (%) by Drug, 2015, 2020 and 2026
Table 5.8 GSK: Flixotide/Flovent Revenue ($m) and AGR (%), 2015-2026
Table 5.9 AstraZeneca: Pulmicort Revenue ($m), AGR (%) and CAGR (%), 2015-2026
Table 5.10 Teva: QVAR Revenue ($m), AGR (%) and CAGR (%), 2015-2026
Table 5.11 Merck: Asmanex Revenue ($m), AGR (%) and CAGR (%), 2015-2026
Table 5.12 Leading Anti-Leukotrienes: Revenues ($m) and Market Shares (%), 2015
Table 5.13 Anti-Leukotrienes Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2015-2026
Table 5.14 Anti-Leukotrienes Market: Market Shares (%) by Drug, 2015, 2020 and 2026
Table 5.15 Merck: Singulair Revenue ($m), AGR (%) and CAGR (%), 2015-2026
Table 5.16 Monoclonal Antibodies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2015-2026
Table 5.17 Monoclonal Antibodies Market: Market Shares (%) by Drug, 2015, 2020 and 2026
Table 5.18 Novartis/Roche: Xolair Asthma Indication Revenue ($m), AGR (%) and CAGR (%), 2015-2026
Table 5.19 Teva: Cinquil Revenue ($m), AGR (%) and CAGR (%), 2015-2026
Table 5.20 GSK: Nucala Revenue ($m), AGR (%) and CAGR (%), 2015-2026
Table 5.21 AstraZeneca/Kyowa Hakko Kirin: Benralizumab Revenue ($m), AGR (%) and CAGR (%), 2015-2026
Table 5.22 Roche: Lebrikizumab Revenue ($m), AGR (%) and CAGR (%), 2015-2026
Table 5.23 Regeneron/Sanofi: Dupilumab Revenue ($m), AGR (%) and CAGR (%), 2015-2026
Table 6.1 Leading Combination Drugs: Revenues ($m) and Market Share (%), 2015
Table 6.2 Combination Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2015-2026
Table 6.3 Combination Drugs Market: Market Shares (%) by Drug, 2015, 2020 and 2026
Table 6.4 GSK: Advair/Seretide Revenue ($m) and AGR (%), 2015-2026
Table 6.5 AstraZeneca: Symbicort Revenue ($m), AGR (%) and CAGR (%), 2015-2026
Table 6.6 Boehringer Ingelheim: Combivent Revenue ($m), AGR (%) and CAGR (%), 2015-2026
Table 6.7 Merck: Dulera Revenue ($m), AGR (%) and CAGR (%), 2015-2026
Table 6.8 GSK: Relvar/Breo Revenue ($m), AGR (%) and CAGR (%), 2015-2026
Table 7.1 World Asthma and COPD Therapies Market: Revenues ($m) and Market Shares (%) by Region, 2015
Table 7.2 World Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by Region, 2015-2026
Table 7.3 Market Shares (%) of Leading Regional Asthma and COPD Therapies Markets, 2015, 2020 and 2026
Table 7.4 World Asthma and COPD Therapies Market: Revenues ($m) and Market Shares (%) by National Market, 2015
Table 7.5 World Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by National Market, 2015-2026
Table 7.5 World Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by National Market, 2015-2026 (continued)
Table 7.6 Market Shares (%) of Leading National Asthma and COPD Therapies Markets, 2015, 2020 and 2026
Table 7.7 US Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2015-2026
Table 7.8 Japanese Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2015-2026
Table 7.9 EU5 Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by National Market, 2015-2026
Table 7.10 German Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2015-2026
Table 7.11 French Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2015-2026
Table 7.12 UK Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2015-2026
Table 7.13 Italian Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2015-2026
Table 7.14 Spanish Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2015-2026
Table 7.15 BRIC Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by National Market, 2015-2026
Table 7.16 Chinese Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2015-2026
Table 7.17 Brazilian Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2015-2026
Table 7.18 Indian Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2015-2026
Table 7.19 Russian Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2015-2026
Table 7.20 Mexican Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2015-2026
Table 8.1 Leading Asthma and COPD Drug Manufacturers: Asthma and COPD Drugs Revenue ($m), Market Share (%), 2015
Table 8.2 Leading Asthma and COPD Drug Manufacturers: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
Table 8.3 Leading Asthma and COPD Drug Manufacturers: Revenues ($m) and Market Shares (%), 2020 and 2026
Table 8.4 GSK: Overview, 2015
Table 8.5 GSK: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2015
Table 8.6 GSK: Asthma and COPD Therapies Revenue ($m), AGR (%),CAGR (%) by Drug, 2015-2026
Table 8.7 GSK: Asthma and COPD Therapies Pipeline, 2015
Table 8.8 Boehringer Ingelheim: Overview, 2015
Table 8.9 Boehringer Ingelheim: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2015
Table 8.10 Boehringer Ingelheim: Asthma and COPD Therapies Revenue ($m), AGR (%) and CAGR (%), by Drug, 2015-2026
Table 8.11 AstraZeneca: Overview, 2015
Table 8.12 AstraZeneca: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2015
Table 8.13 AstraZeneca: Asthma and COPD Therapies Revenue ($m), AGR (%) and CAGR (%), by Drug, 2015-2026
Table 8.14 AstraZeneca: Asthma and COPD Therapies Pipeline, 2016
Table 8.15 Merck: Overview, 2015
Table 8.16 Merck: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2015
Table 8.17 Merck: Asthma and COPD Therapies Revenue ($m), AGR (%),CAGR (%) by Drug, 2015-2026
Table 8.18 Novartis: Overview, 2015
Table 8.19 Novartis: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2015
Table 8.20 Novartis: Asthma and COPD Therapies Revenue ($m), AGR (%),CAGR (%) by Drug, 2015-2026
Table 8.21 Novartis: Asthma and COPD Therapies Pipeline, 2015
Table 8.22 Roche: Overview, 2015
Table 8.23 Roche: Asthma and COPD Therapies Revenue ($m), AGR (%),CAGR (%) by Drug, 2015-2026
Table 8.24 Teva: Overview, 2015
Table 8.25 Teva: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2015
Table 8.26 Teva: Asthma and COPD Therapies Revenue ($m), AGR (%),CAGR (%) by Drug, 2015-2026
Table 8.27 Teva: Asthma and COPD Therapies Pipeline, 2015
Table 9.1 Bronchodilators Pipeline: Selected Phase 3 Drugs, 2016
Table 9.2 Anti-Inflammatory Drugs Pipeline: Selected Phase 3 Drugs, 2016
Table 9.3 Combination Drugs Pipeline: Selected Phase 3 Drugs, 2016
Table 9.4 Other Asthma and COPD Drugs Pipeline, 2016

Table of Figures
Figure 1.1 Global Asthma and COPD Therapies Market Segmentation Overview, 2016
Figure 2.1 Summary of GINA Guidance for Asthma Treatment, 2016
Figure 2.2 Summary of GOLD Guidance for COPD Treatment, 2016
Figure 3.1 World Respiratory Drugs Market: Revenues ($m) by Therapeutic Area, 2015
Figure 3.2 World Respiratory Drugs Market: Market Shares (%) by Therapeutic Area, 2015
Figure 3.3 Top 10 Asthma and COPD Therapies: Market Shares (%), 2015
Figure 3.4 World Asthma and COPD Therapies Market Forecast: Revenue ($m) and AGR (%), 2015-2026
Figure 3.5 World Asthma Therapies Market Forecast: Revenue ($m) and AGR (%), 2015-2026
Figure 3.6 World COPD Therapies Market Forecast: Revenue ($m) and AGR (%), 2015-2026
Figure 3.8 Global Asthma and COPD Therapies Market: Market Shares (%) by Segment, 2015
Figure 3.9 Global Asthma and COPD Therapies Market: Market Shares (%) by Segment, 2020
Figure 3.10 Global Asthma and COPD Therapies Market: Market Shares (%) by Segment, 2026
Figure 3.11 World Asthma and COPD Therapies Market: Drivers and Restraints, 2016-2026
Figure 4.1 Bronchodilator Monotherapy Market: Revenues ($m) by Drug Class, 2015
Figure 4.2 Bronchodilator Monotherapy Market: Market Shares (%) by Drug Class, 2020
Figure 4.3 Bronchodilator Monotherapy Market: Market Shares (%) by Drug Class, 2026
Figure 4.4 Bronchodilator Monotherapy Market Forecast: Revenue ($m) and AGR (%), 2015-2026
Figure 4.5 Anticholinergics Market Forecast: Revenue ($m) and AGR (%), 2015-2026
Figure 4.6 Anticholinergics Market: Market Shares (%) by Drug, 2015
Figure 4.7 Anticholinergics Market: Market Shares (%) by Drug, 2020
Figure 4.8 Anticholinergics Market: Market Shares (%) by Drug, 2026
Figure 4.9 Boehringer Ingelheim: Spiriva Revenue ($m) and AGR (%), 2015-2026
Figure 4.10 Boehringer Ingelheim: Atrovent Revenue ($m) and AGR (%), 2015-2026
Figure 4.11 AstraZeneca/Menarini: Eklira/Tudorza/Bretaris Revenue ($m) and AGR (%), 2015-2026
Figure 4.12 SABAs Market Forecast: Revenue ($m) and AGR (%), 2015-2026
Figure 4.13 SABAs Market: Market Shares (%) by Drug, 2015
Figure 4.14 SABAs Market: Market Shares (%) by Drug, 2020
Figure 4.15 SABAs Market: Market Shares (%) by Drug, 2026
Figure 4.16 GSK: Ventolin Revenue ($m) and AGR (%), 2015-2026
Figure 4.17 Teva: ProAir Revenue ($m) and AGR (%), 2015-2026
Figure 4.18 Merck: Proventil Revenue ($m) and AGR (%), 2015-2026
Figure 4.19 Dainippon Sumitomo: Xopenex Revenue ($m) and AGR (%), 2015-2026
Figure 4.20 LABAs Market Forecast: Revenue ($m) and AGR (%), 2015-2026
Figure 4.21 LABAs Market: Market Shares (%) by Drug, 2015
Figure 4.22 LABAs Market: Market Shares (%) by Drug, 2020
Figure 4.23 LABAs Market: Market Shares (%) by Drug, 2026
Figure 4.24 Merck/Novartis: Foradil Revenue ($m) and AGR (%), 2015-2026
Figure 4.25 Dainippon Sumitomo: Brovana Revenue ($m) and AGR (%), 2015-2026
Figure 4.26 Novartis: Arcapta/Onbrez Revenue ($m) and AGR (%), 2015-2026
Figure 4.27 GSK: Serevent Revenue ($m) and AGR (%), 2015-2026
Figure 5.1 Anti-Inflammatory Drugs Market: Revenues ($m) by Drug Class, 2015
Figure 5.2 Anti-Inflammatory Drugs Market: Market Shares (%) by Drug Class, 2015
Figure 5.3 Anti-Inflammatory Drugs Market Forecast: Revenue ($m) and AGR (%), 2015-2026
Figure 5.4 Anti-Inflammatory Drugs Market: Revenues ($m) by Drug Class, 2020
Figure 5.5 Anti-Inflammatory Drugs Market: Market Shares (%) by Drug Class, 2020
Figure 5.6 Anti-Inflammatory Drugs Market: Revenues ($m) by Drug Class, 2025
Figure 5.7 Anti-Inflammatory Drugs Market: Market Shares (%) by Drug Class, 2025
Figure 5.8 Corticosteroids Market Forecast: Revenue ($m) and AGR (%), 2015-2026
Figure 5.9 Corticosteroids Market: Market Share (%) by Drug, 2015
Figure 5.10 Corticosteroids Market: Market Share (%) by Drug, 2020
Figure 5.11 Corticosteroids Market: Market Share (%) by Drug, 2026
Figure 5.12 GSK: Flixotide/Flovent Revenue ($m) and AGR (%), 2015-2026
Figure 5.13 AstraZeneca: Pulmicort Revenue ($m) and AGR (%), 2015-2026
Figure 5.14 Teva: QVAR Revenue ($m) and AGR (%), 2015-2026
Figure 5.15 Merck: Asmanex Revenue ($m) and AGR (%), 2015-2026
Figure 5.16 Anti-Leukotrienes Market Forecast: Revenue ($m) and AGR (%), 2015-2026
Figure 5.17 Anti-Leukotrienes Market: Market Shares (%) by Drug, 2015
Figure 5.18 Anti-Leukotrienes Market: Market Shares (%) by Drug, 2020
Figure 5.19 Anti-Leukotrienes Market: Market Shares (%) by Drug, 2026
Figure 5.20 Merck: Singulair Revenue ($m) and AGR (%), 2015-2026
Figure 5.21 Monoclonal Antibodies Market Forecast: Revenue ($m) and AGR (%), 2015-2026
Figure 5.22 Monoclonal Antibodies Market: Market Shares (%) by Drug, 2020
Figure 5.23 Monoclonal Antibodies Market: Market Shares (%) by Drug, 2026
Figure 5.24 Novartis/Roche: Xolair Asthma Indication Revenue ($m) and AGR (%), 2015-2026
Figure 5.25 Teva: Cinquil Revenue ($m) and AGR (%), 2015-2026
Figure 5.26 GSK: Nucala Revenue ($m) and AGR (%), 2015-2026
Figure 5.27 AstraZeneca/Kyowa Hakko Kirin: Benralizumab Revenue ($m) and AGR (%), 2015-2026
Figure 5.28 Roche: Lebrikizumab Revenue ($m) and AGR (%), 2015-2026
Figure 5.29 Regeneron/Sanofi: Dupilumab Revenue ($m) and AGR (%), 2015-2026
Figure 6.1 Combination Drugs Market Forecast: Revenue ($m) and AGR (%), 2015-2026
Figure 6.2 Combination Drugs Market: Market Shares (%) by Drug, 2015
Figure 6.3 Combination Drugs Market: Market Shares (%) by Drug, 2020
Figure 6.4 Combination Drugs Market: Market Shares (%) by Drug, 2026
Figure 6.5 GSK: Advair/Seretide Revenue ($m) and AGR (%), 2015-2026
Figure 6.6 AstraZeneca: Symbicort Revenue ($m) and AGR (%), 2015-2026
Figure 6.7 Boehringer Ingelheim: Combivent Revenue ($m) and AGR (%), 2015-2026
Figure 6.8 Merck: Dulera Revenue ($m) and AGR (%), 2015-2026
Figure 6.9 GSK: Relvar/Breo Revenue ($m) and AGR (%), 2015-2026
Figure 7.1 World Asthma and COPD Therapies Market: Revenues ($m) by Region, 2015
Figure 7.2 World Asthma and COPD Therapies Market: Market Shares (%) by Region, 2015
Figure 7.3 World Asthma and COPD Therapies Market Forecast: Revenues ($m) by Region, 2015-2026
Figure 7.4 World Asthma and COPD Therapies Market: Market Shares (%) by Region, 2020
Figure 7.5 World Asthma and COPD Therapies Market: Market Shares (%) by Region, 2026
Figure 7.6 World Asthma and COPD Therapies Market: Revenues ($m) by National Market, 2015
Figure 7.7 World Asthma and COPD Therapies Market: Market Shares (%) by National Market, 2015
Figure 7.8 World Asthma and COPD Therapies Market: Market Shares (%) by National Market, 2020
Figure 7.9 World Asthma and COPD Therapies Market: Market Shares (%) by National Market, 2026
Figure 7.10 US Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2015-2026
Figure 7.11 Japanese Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2015-2026
Figure 7.12 EU5 Asthma and COPD Therapies Market Forecast: Revenues ($m) by National Market, 2015-2026
Figure 7.13 German Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2015-2026
Figure 7.14 French Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2015-2026
Figure 7.15 UK Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and 2015-2026
Figure 7.16 Italian Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2015-2026
Figure 7.17 Spanish Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2015-2026
Figure 7.18 BRIC Asthma and COPD Therapies Market Forecast: Revenues ($m) by National Market, 2015-2026
Figure 7.19 Chinese Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2015-2026
Figure 7.20 Brazilian Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2015-2026
Figure 7.21 Indian Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2015-2026
Figure 7.22 Russian Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2015-2026
Figure 7.23 Mexican Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2015-2026
Figure 8.1 Leading Asthma and COPD Drug Manufacturers: Revenue ($m), 2015
Figure 8.2 Leading Asthma and COPD Drug Manufacturers: Market Share (%), 2015
Figure 8.3 Leading Asthma and COPD Drug Manufacturers: Revenues ($m), 2020
Figure 8.4 Leading Asthma and COPD Drug Manufacturers: Market Shares (%), 2020
Figure 8.5 Leading Asthma and COPD Drug Manufacturers: Revenues ($m), 2026
Figure 8.6 Leading Asthma and COPD Drug Manufacturers: Market Shares (%), 2026
Figure 8.7 GSK: Asthma and COPD Therapies Revenue ($m) by Drug, 2015
Figure 8.8 GSK: Asthma and COPD Therapies Revenue Share (%) by Drug, 2015
Figure 8.9 GSK: Asthma and COPD Therapies Revenue ($m) and AGR (%), 2015-2026
Figure 8.10 Boehringer Ingelheim: Asthma and COPD Therapies Revenue ($m) by Drug, 2015
Figure 8.11 Boehringer Ingelheim: Asthma and COPD Therapies Revenue Share (%) by Drug, 2015
Figure 8.12 Boehringer Ingelheim: Asthma and COPD Therapies Revenue ($m) and AGR (%), 2015-2026
Figure 8.13 AstraZeneca: Asthma and COPD Therapies Revenue ($m) by Drug, 2015
Figure 8.14 AstraZeneca: Asthma and COPD Therapies Revenue Share (%) by Drug, 2015
Figure 8.15 AstraZeneca: Asthma and COPD Therapies Revenue ($m) and AGR (%), 2015-2026
Figure 8.16 Merck: Asthma and COPD Therapies Revenue ($m) by Drug, 2015
Figure 8.17 Merck: Asthma and COPD Therapies Revenue Share (%) by Drug, 2015
Figure 8.18 Merck: Asthma and COPD Therapies Revenue ($m) and AGR (%), 2015-2026
Figure 8.19 Novartis: Asthma and COPD Therapies Revenue ($m) by Drug, 2015
Figure 8.20 Novartis: Asthma and COPD Therapies Revenue Share (%) by Drug, 2015
Figure 8.21 Novartis: Asthma and COPD Therapies Revenue ($m) and AGR (%), 2015-2026
Figure 8.22 Roche: Asthma and COPD Therapies Revenue ($m) and AGR (%), 2015-2026
Figure 8.23 Teva: Asthma and COPD Therapies Revenue ($m) by Drug, 2015
Figure 8.24 Teva: Asthma and COPD Therapies Revenue Share (%) by Drug, 2015
Figure 8.25 Teva: Asthma and COPD Therapies Revenue ($m) and AGR (%), 2015-2026
Figure 10.1 Asthma and COPD Therapies Market: Strengths and Weaknesses, 2016-2026
Figure 10.2 Asthma and COPD Therapies Market: Opportunities and Threats, 2016-2026
Figure 10.3 Porter’s Five Forces Analysis of the Asthma and COPD Therapies Market, 2016-2026
Figure 12.1 World Asthma and COPD Therapies Market Forecast: Revenues ($m) by Therapeutic Area, 2015-2026

★調査レポート[喘息&COPDの世界市場2016-2026] ( Asthma & COPD Market Report 2016-2026 / VGAIN61125) 販売に関する免責事項
[喘息&COPDの世界市場2016-2026] ( Asthma & COPD Market Report 2016-2026 / VGAIN61125) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆